ライフサイエンスコーパス: protective immunity

1 hat supports tissue homeostasis and provides protective immunity.

2 rt viral replication despite the presence of protective immunity.

3 ent approaches for their ability to generate protective immunity.

4 rstanding of the immunological correlates of protective immunity.

5 inst this protein region is not essential to protective immunity.

6 sing this information to identify targets of protective immunity.

7 ific role for P2X5 as a critical mediator of protective immunity.

8 pe IgG1 antibody levels were associated with protective immunity.

9 and expanding the TCR repertoire to improve protective immunity.

10 simultaneous up- and down-regulation of host protective immunity.

11 for determining correlates and mechanisms of protective immunity.

12 on vaccines with potential to confer broadly protective immunity.

13 response to LPS is an important component of protective immunity.

14 nvelope antibodies play an important role in protective immunity.

15 for long periods of time and mediate durable protective immunity.

16 inflammation while preserving and enhancing protective immunity.

17 , indicating the generation of CT26-specific protective immunity.

18 phagocytosis (ADCP) activity, implicated in protective immunity.

19 s, two immunodominant antigens implicated in protective immunity.

20 eting distinct epitopes may be necessary for protective immunity.

21 inform ZIKV vaccine strategies for inducing protective immunity.

22 tabolism to persist in tissue and to mediate protective immunity.

23 and that antineuraminidase antibodies offer protective immunity.

24 l for DC maturation, which may contribute to protective immunity.

25 ith negligible off-target effects, to induce protective immunity.

26 igens can be sufficient for parasite-induced protective immunity.

27 innate immunity and its poor elicitation of protective immunity.

28 h we urgently need a better understanding of protective immunity.

29 ent of IL-17-dependent, Th cell-transferable protective immunity.

30 is study establishes a new minimal length of protective immunity.

31 tural killer (NK) cells were dispensable for protective immunity.

32 nological memory to vaccines is critical for protective immunity.

33 ow recognized as a syndrome of aberrant host protective immunity.

34 PfCSP-reactive B cells in PfSPZ-CVac-induced protective immunity.

35 leads to T cell dysfunction and compromised protective immunity.

36 or models, including complete responses with protective immunity.

37 may contain important epitopes for inducing protective immunity.

38 of VM cells, including their likely role in protective immunity.

39 ork for designing vaccines to elicit similar protective immunity.

40 but they require about 5 to 7 days to induce protective immunity.

41 nce to virus or viral components, can induce protective immunity.

42 antigen misfolding, hindering generation of protective immunity.

43 tion following vaccination in the absence of protective immunity.

44 been impeded by the absence of correlates of protective immunity.

45 ed by poor understanding of what constitutes protective immunity.

46 (+) memory T lymphocytes that participate in protective immunity.

47 n targeting blood-stage parasites results in protective immunity.

48 ant glycoprotein in serum and is crucial for protective immunity.

49 generating IFN-alpha/beta-induced subsequent protective immunity.

50 h direct tumor killing and the triggering of protective immunity.

51 nd NS1 vaccination confers antibody-mediated protective immunity.

52 g of the requirements for induction of fully protective immunity.

53 oping parasites in hepatocytes, resulting in protective immunity.

54 e portals of infection and provide long-term protective immunity.

55 rently and has key roles in Ab responses and protective immunity.

56 nk inductive and effector phases to generate protective immunity.

57 I IFNs recruits immune effectors to promote protective immunity.

58 ve QFN-CMV assay compared with those without protective immunity (13% versus 67%, P = 0.0003), as was

59 -transfer experiments also revealed that the protective immunity afforded by vaccination with the bat

60 t lead to the initiation of CD8 TRM-mediated protective immunity after viral infection are unclear.

61 is system is the first capable of generating protective immunity against a broad spectrum of lethal p

62 erior humoral immune responses and conferred protective immunity against a lethal challenge dose of h

63 observable toxicity in animals and achieved protective immunity against a lethal influenza challenge

64 these findings suggest that vaccine-induced protective immunity against a murine model of experiment

65 nstrate that CD8(+) T cells are required for protective immunity against a naturally occurring murine

66 we evaluated whether alpha-GalCer generates protective immunity against a swine influenza (SI) virus

67 orm to gain insights regarding mechanisms of protective immunity against B. mallei and B. pseudomalle

68 As IFN-gamma is essential for protective immunity against Bp we investigated how IFN-g

69 des]) C-terminal region, was shown to elicit protective immunity against C. difficile and is under co

70 This process may impair protective immunity against certain opportunistic infect

71 To provide protective immunity against circulating primary HIV-1 st

72 Protective immunity against Coxiella burnetii infection

73 Persistent parasites play a vital role in protective immunity against disease pathology upon reinf

74 This does not induce broad, cross protective immunity against emergent subtypes.

75 Immune homeostasis is a prerequisite to protective immunity against gastrointestinal infections.

76 demonstrate that IL-25 is critical for host protective immunity against H. polygyrus bakeri infectio

77 promising candidates to examine induction of protective immunity against heterologous pathogens.

78 as a practical and effective route to induce protective immunity against HIV-1.

79 no detectable virus replication, indicating protective immunity against homologous strains.

80 ults highlight the difficulties in eliciting protective immunity against immunodeficiency virus infec

81 T cells provide protective immunity against infections by differentiatin

82 tes with downstream CD8(+) T cell memory and protective immunity against infectious challenge.

83 Vaccination is widely used to generate protective immunity against influenza virus.

84 D8 T cell immunity is considered optimal for protective immunity against intracellular Ags.

85 proaches have had great difficulty achieving protective immunity against it in rhesus monkey models.

86 dicates that DCs are dispensable as APCs for protective immunity against LCMV infection.

87 Interestingly, vDeltaK1L conferred protective immunity against lethal VACV challenge.

88 Several studies suggest the existence of protective immunity against LF in humans.

89 ducible large GTPase which is crucial to the protective immunity against microorganisms.

90 ce that exceed the threshold correlated with protective immunity against multiple strains of Zika vir

91 CD4 T cells are critical for protective immunity against Mycobacterium tuberculosis (

92 ng CD107(ab+) CD4(+) T cells associated with protective immunity against ocular herpes infection and

93 ponse in the cornea that was associated with protective immunity against ocular herpes.

94 ific CD8(+) TEM cells associated with strong protective immunity against ocular herpesvirus infection

95 ecific CD8(+) T cells associated with strong protective immunity against ocular herpesvirus infection

96 These results suggest that protective immunity against P. falciparum can be achieve

97 d the role of these functional antibodies in protective immunity against P. vivax malaria.

98 CD4 TEMRA cells have been implicated in protective immunity against pathogens such as dengue vir

99 es and also as valuable tools to interrogate protective immunity against Plasmodium infection.

100 R4 with rickettsial LPS, contributes to host protective immunity against R. australis These findings

101 data show that SARS-CoV-2 infection induced protective immunity against reexposure in nonhuman prima

102 whether infection with SARS-CoV-2 results in protective immunity against reexposure.

103 nfection of ERBs with MARV induces long-term protective immunity against reinfection and indicates th

104 occur but is a rare phenomenon suggestive of protective immunity against reinfection that lasts for a

105 ed to better understand the requirements for protective immunity against S. aureus.

106 tative of most Covid-19 patients, long-lived protective immunity against SARS-CoV-2 after primary inf

107 Serological immunoassays that can identify protective immunity against SARS-CoV-2 are needed to ada

108 ns as a candidate vectored vaccine to elicit protective immunity against SARS-CoV-2.

109 ntly needed to define clinical correlates of protective immunity against SARS-CoV-2.

110 in studies verifying diagnostic accuracy and protective immunity against SARS-CoV-2.

111 e efficacy of these NP adjuvants in inducing protective immunity against simian immunodeficiency viru

112 based vaccine candidates that elicit broadly protective immunity against Strep A.

113 cination with the batA mutant strain elicits protective immunity against subsequent infection with wi

114 cells play a central role in development of protective immunity against TB, in which they participat

115 In addition, the protective immunity against the cysts remains largely un

116 he H1N1 infection but did not generate cross-protective immunity against the H3N2 influenza strain.

117 x (MHC) class II molecules are essential for protective immunity against them.

118 n attractive vaccine candidate and marker of protective immunity against tuberculosis, although the m

119 While first infection confers long-term protective immunity against viruses of the infecting ser

120 ues (Macaca fascicularis), and-concomitantly-protective immunity against yellow fever virus.

121 a SseB with flagellin substantially enhances protective immunity, allowing immunized C57BL/6 mice to

122 robust identification of the true targets of protective immunity ambiguous.

123 pproach, we confirmed CD4(+) T cell-mediated protective immunity and a CD8(+) T cell-dependent pathog

124 at IL-25 signaling subverts the induction of protective immunity and amplifies the type 2 immune resp

125 mechanism has likely evolved to both sustain protective immunity and avoid autoantibody production.

126 drive human cancer progression by thwarting protective immunity and could lead to immunotherapy for

127 ng the impact of OAS phenotype antibodies on protective immunity and disease severity in secondary in

128 der disease will support an understanding of protective immunity and highlights the potential of incl

129 nate lymphoid cells (ILCs) contribute to the protective immunity and homeostasis of the gut, and the

130 ses in diverse tissue sites are critical for protective immunity and homeostasis.

131 rus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab ther

132 ovide insights into the cellular features of protective immunity and identify novel therapeutic targe

133 nses is important for defining correlates of protective immunity and identifying effective vaccine an

134 tion of T cell subsets is important for both protective immunity and immunoregulation.

135 of considerable importance for understanding protective immunity and improved vaccine design.

136 r and describe how macrophages change during protective immunity and inflammation.

137 innate immune system that can contribute to protective immunity and inflammation.

138 ons can enhance our understanding of malaria-protective immunity and inform the design of disease-mod

139 e T-cell homeostasis is essential to promote protective immunity and limit autoimmunity and neoplasia

140 er of immunological checkpoints that promote protective immunity and maintain tolerance.

141 as for anthrax, for which rapid induction of protective immunity and memory with a single injection i

142 be the most effective antigens for inducing protective immunity and non-envelope-specific T cell res

143 sponses, interfering with the development of protective immunity and parasite clearance.

144 t neonatal HSV (nHSV) infection by providing protective immunity and preventing perinatal transmissio

145 ogenes infection inhibited the generation of protective immunity and specifically the activation of a

146 ne aging results in progressive loss of both protective immunity and T cell-mediated suppression, the

147 d wild-type (WT) mice have similar levels of protective immunity and the absence of IFN-gamma-produci

148 Rationale: There is poor understanding about protective immunity and the pathogenesis of cavitation i

149 -modified mRNA-LNP elicits rapid and durable protective immunity and therefore represents a new and p

150 mma secretion and signaling were critical to protective immunity and were profoundly augmented by CD1

151 RhIV infection elicited protective immunity, and antibodies to HIV-1 Env that we

152 ld further be explored for associations with protective immunity, and cross-reactivity with other exp

153 Vaccine efficacy is attributed to long-term protective immunity, and understanding the parameters th

154 ns, including virus adsorption, induction of protective immunity, and virulence in swine.

155 ogens, we validate that the prime targets of protective immunity are conformational epitopes at the d

156 sis, although the mechanisms underlying this protective immunity are not fully understood.

157 Although correlates for protective immunity are not yet known, opsonophagocytic

158 ll responses.IgE is an important mediator of protective immunity as well as allergic reaction, but ho

159 e in transmission, risks for severe disease, protective immunity, as well as novel therapies and vacc

160 ays, which may not provide a true measure of protective immunity associated with H7 immunization.

161 +)CD127(+)cells that are implicated in early protective immunity at mucosal surfaces.

162 is a novel mechanism to induce specific and protective immunity at sites of viral infection.

163 ally delivered vaccines are unable to induce protective immunity at these surfaces.

164 (+) T cell memory is essential for long-term protective immunity but is often compromised in cancer,

165 ously drift, which allows them to circumvent protective immunity, but conserved epitopes provide immu

166 te pathogenic autoimmune cells while sparing protective immunity, but feasible strategies for such an

167 ovirus is an avirulent pathogen that elicits protective immunity, but we discovered that it can nonet

168 focus of vaccine research aimed at inducing protective immunity by antibodies as well as efforts to

169 ne/threonine kinase Akt in the generation of protective immunity by CD8(+) T cells.

170 We quantify the dynamics of protective immunity by fitting individual-level mechanis

171 Therefore, SPTLC2 underpins protective immunity by translating extracellular stimuli

172 re, we have pursued a strategy for eliciting protective immunity by vaccinating with small molecules

173 emonstrated the earliest time point at which protective immunity can be achieved in children with ALL

174 trated that the earliest time point at which protective immunity can be achieved in children with ALL

175 es triggered and the rapid kinetics by which protective immunity can be attained after a single dose

176 trate that by disrupting it much more robust protective immunity can be generated, providing a pathwa

177 lts show that this new LAIV elicits improved protective immunity compared to a more conventional LAIV

178 to establish the occurrence/degree of cross-protective immunity conferred across sCoVs and with COVI

179 We further explored the potential for cross-protective immunity conferred by prior exposure to four

180 pre-existing anti-vector immune responses on protective immunity conferred by this vaccine platform i

181 e-causing allergen with the goal to induce a protective immunity consisting of allergen-specific bloc

182 tivity, as well as its multifaceted roles in protective immunity, control of mast cell homeostasis, a

183 ice with a C. neoformans strain that induces protective immunity demonstrated that recruitment of pDC

184 ts in our understanding of the mechanisms of protective immunity, demonstrating a need to measure epi

185 nses to malaria play important roles in both protective immunity development and pathogenesis.

186 The presence or absence of protective immunity due to infection or vaccination (whe

187 ion by Toxoplasma gondii triggers a lifelong protective immunity due to the persistence of parasitic

188 ance that interferes with the development of protective immunity during childhood.

189 subset of gammadelta T cells contributes to protective immunity during the blood stage in naive host

190 CD4(+) T cells that regulate a protective immunity during the neurodegenerative process

191 However, T cells are also critical in protective immunity, especially in immune-compromised pa

192 ical components necessary for eliciting this protective immunity, evaluate the breadth of the protect

193 hown to induce complete tumor regression and protective immunity following intralesional treatment of

194 s) are critical for the rapid development of protective immunity following re-infection.

195 epidemiologic settings and demonstration of protective immunity for GII infections provide support f

196 hylococcus aureus does not induce long-lived protective immunity for reasons that are not completely

197 gests important roles for T(RM) in mediating protective immunity, fundamental aspects of the populati

198 Knowledge of how S. aureus manipulates protective immunity has been hampered by a lack of antig

199 However, to date, studies on protective immunity have been performed only in animal m

200 f Plasmodium vivax reticulocyte invasion and protective immunity have hampered development of vivax v

201 s concerning the prevalence and longevity of protective immunity have left vulnerable communities fea

202 vestigations into virus-host interactions in protective immunity, host susceptibility, and virus path

203 studies typically examined the biomarkers of protective immunity however the biomarkers of attenuatio

204 lose important epitopes for inducing robust protective immunity.IMPORTANCE The emerging, highly viru

205 dermal model of infection yet still elicited protective immunity.IMPORTANCE The vaccinia virus (VACV)

206 antibody titers were above the threshold for protective immunity in all 78 samples analyzed.

207 associated with invasive strains and elicit protective immunity in animal models.

208 ania donovani parasites (LdCen (-/-)) showed protective immunity in animal models.

209 d prefusion F protein can robustly stimulate protective immunity in animals previously infected with

210 resident memory (Trm) CD8(+) T cells mediate protective immunity in barrier tissues, but the cues pro

211 ported to be associated with vaccine-induced protective immunity in challenge studies involving nonhu

212 We also demonstrated maternal protective immunity in challenged newborn mice born to f

213 ditive amounts of interferons and stimulated protective immunity in chickens.

214 lower respiratory tract and triggered strong protective immunity in cotton rats.

215 roles for both CD4(+) and CD8(+) T cells in protective immunity in COVID-19.

216 d to understand major determinants impairing protective immunity in early stage of disease.See relate

217 gens could lead to a better understanding of protective immunity in human cholera.

218 from innate cells can be utilized to elicit protective immunity in immune deficient persons.

219 S and does not interfere with development of protective immunity in immunized mice.

220 strongly attenuated in virulence and induced protective immunity in mice.

221 tosolic multiprotein complexes that initiate protective immunity in response to infection, and can al

222 cells that might lead to immunopathology or protective immunity in severe COVID-19, we applied singl

223 of the GIT is not necessary for induction of protective immunity in the FRT, a finding that is import

224 oreover, by lowering opportunities for cross-protective immunity in the population, conventional vacc

225 e strategy is effective at inducing complete protective immunity in the rat RHV model.

226 elanocortin-adenosinergic pathways to induce protective immunity in uveitic patients.

227 rovirus antigenic structure and the basis of protective immunity, in this work we produced a panel of

228 The protective immunity induced by alpha-Gal is ensured thro

229 Since protective immunity induced by IKEPLUS is dependent on a

230 ggest that neutrophils are indispensable for protective immunity induced by LdCen(-/-) parasite vacci

231 ng the high-avidity epitope SSIEFARL induced protective immunity irrespective of gene expression cont

232 Because vaccine-induced protective immunity is critically determined by HIV enve

233 n Ostertagia ostertagi (OO)-infected cattle, protective immunity is slow to develop, and partial prot

234 vaccination can result in failure to develop protective immunity leaving individuals at risk for infe

235 an important role in immune surveillance and protective immunity, mainly through rapid cytokine relea

236 ivity suggesting that epitopes involved with protective immunity may be more complex than previously

237 Vaccines that induce nonpathogenic protective immunity may soon be available, and it is pos

238 We uncover two inter-organ mechanisms of protective immunity mediated by soluble and cellular fac

239 However, the importance of PKCeta in protective immunity mediated by T effector cells remains

240 This chimeric protein elicits protective immunity, mediated by CD4(+) T cells and neut

241 CD4(+) T cells contribute in diverse ways to protective immunity, most notably, in the provision of h

242 osal delivery would ensure the best onset of protective immunity, most of the candidate vaccines are

243 proved recognition of epitopes important for protective immunity, namely, V2-specific humoral immune

244 ood ratio rest, P <= .05) contributed to the protective immunity observed with the IgG3 antibodies.

245 juvant properties that improve SseB-mediated protective immunity provided by circulating memory.

246 e found that the vaccine candidates elicited protective immunity related to the production of neutral

247 sceptible C57BL/6 mice, but the mechanism of protective immunity remains undefined.

248 Finally, protective immunity required host expression of IFN-gamm

249 e viral vectored vaccines efficiently induce protective immunity, some concerns remain to be solved.

250 he first innate immune cells to elicit early protective immunity that controls invading viral pathoge

251 nd interferon upregulation all contribute to protective immunity that occurs in humans following infl

252 ior to LPA challenge is capable of eliciting protective immunity that significantly reduces splenomeg

253 doxically exert antitumor activity and prime protective immunity, the pathways driving this phenotype

254 tion in a critical temporal window to impede protective immunity through cytotoxic-T-lymphocyte-assoc

255 erstanding of the mechanisms involved in the protective immunity to alpha-Gal and discuss the possibi

256 1 and Th17 cells have an established role in protective immunity to Bordetella pertussis, but this ev

257 PI-WVC stimulates protective immunity to C. burnetii in mice through stimu

258 not understand the mechanisms that underlie protective immunity to Cryptosporidium.

259 Protective immunity to cutaneous leishmaniasis is mediat

260 dentity of the specific microbes that elicit protective immunity to different infections is less clea

261 H1N1 influenza and determined clearance and protective immunity to H3N2 virus.

262 sponses are necessary for the development of protective immunity to helminth parasites but also cause

263 , when challenged with H3N2, generated cross-protective immunity to heterosubtypic H3N2 influenza str

264 tentially novel correlates and mechanisms of protective immunity to HIV vaccination, thus offering a

265 therefore not surprising that elicitation of protective immunity to HIV-1 has not yet been possible.

266 d to the HA stalk of IBV contribute to cross-protective immunity to IBV of both lineages.

267 gammadelta T cells play a role in protective immunity to infection at mucosal surface, but

268 CD4 T cells are a central component of protective immunity to influenza, delivering direct effe

269 uenza A virus (IAV) and were responsible for protective immunity to lethal challenge with pathogenic

270 g molecules appear to play integral roles in protective immunity to liver-stage malaria.

271 nexposed populations, which have not evolved protective immunity to M. gallisepticum We show using 3

272 her delineate mechanisms whereby HIV impairs protective immunity to M. tuberculosis, we evaluated the

273 m of tolerance, there is concurrent need for protective immunity to meet the antigenic challenges enc

274 esults emphasize the importance of providing protective immunity to neonates during this window of vu

275 chi10069(pYA5199) as an oral vaccine induces protective immunity to prevent bubonic and pneumonic pla

276 IL-10 deficiency in mice restores protective immunity to S. aureus infection, and adjuvanc

277 mimics human infection, we show that lack of protective immunity to S. aureus systemic reinfection is

278 ause of monogenic inborn errors that disrupt protective immunity to SARS-CoV-2.

279 An understanding of protective immunity to severe acute respiratory syndrome

280 , but infection does not result in long-term protective immunity to subsequent infections.

281 s, which in turn inhibits the development of protective immunity to the infection.

282 Treatment with mAb to IL-10 restored protective immunity to the mutant mice.

283 oV-2 has become pandemic and the duration of protective immunity to the virus is unknown.

284 tructure that remodeled our understanding of protective immunity to this important pathogen.

285 rcome a defect of CD4(+) T cells in inducing protective immunity to vaccination with a T-dependent in

286 Cytotoxic T cells are essential mediators of protective immunity to viral infection and malignant tum

287 ritical for the production of antibodies and protective immunity to viruses.

288 r, we currently do not know the longevity of protective immunity to ZIKV after a person becomes infec

289 -specific CD4(+) T cells that can potentiate protective immunity upon influenza virus infection.IMPOR

290 ional profiles suggest a capacity to mediate protective immunity via antigen non-specific bystander k

291 antibody-dependent mechanisms contribute to protective immunity via distinct targets whose identific

292 infected Rel(C307X) animals, indicated that protective immunity was also compromised in these mice.

293 In addition, protective immunity was effectively transferred in circu

294 fication to reduce NLRC4 activation enhances protective immunity, which could have important implicat

295 ysts in the host or the presence of lifelong protective immunity, which led us to question this dogma

296 Our work reveals a fetal-specific program of protective immunity whose dysregulation is associated wi

297 trial, which demonstrated a rapid waning of protective immunity with time, have underscored the need

298 l tumor-associated stroma (TAS) to configure protective immunity within the tumor microenvironment.

299 A potent adjuvant that induces strong protective immunity without incurring any significant sk

300 cific Abs are typically a major predictor of protective immunity, yet human B cell and Ab responses d